Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Thursday, Viatris Inc (NASDAQ:VTRS) reported first-quarter EPS of $0.67, which is in line with the consensus.
週四，維亞特里斯公司（納斯達克股票代碼：VTRS）公佈的第一季度每股收益爲0.67美元，符合市場共識。
The company reported sales of $3.66 billion, missing the consensus of $3.69 billion. Total net sales declined 2% on a reported basis and increased 2% on a divestiture-adjusted operational basis.
該公司報告的銷售額爲36.6億美元，未達到共識的36.9億美元。根據報告，總淨銷售額下降了2％，經剝離調整後的運營基礎上增長了2％。
Brand sales fell 5% to $2.31 billion. The company says the performance reflects strong growth in Emerging Markets and Europe and expansion of business activities in JANZ, offset by unfavorable channel dynamics in North America and expected base business erosion resulting from government price regulations in Japan and Australia.
品牌銷售額下降了5％，至23.1億美元。該公司表示，該業績反映了新興市場和歐洲的強勁增長以及JANZ業務活動的擴張，但被北美不利的渠道動態以及日本和澳大利亞政府價格監管導致的預期基礎業務侵蝕所抵消。
Generic sales reached 1.34 billion, up 4%. Viatris says growth is driven by strong new product launch performance in Developed Markets, along with the improved performance of Wixela and solid performance across broader portfolios in Developed and Emerging Markets.
仿製藥銷售額達到13.4億美元，增長4％。維亞特里斯表示，增長是由發達市場強勁的新產品發佈表現，以及Wixela業績的改善以及發達和新興市場更廣泛投資組合的穩健表現推動的。
"As a result of our underlying fundamentals and the momentum of our business, we believe we are well positioned to meet our 2024 financial guidance, as well as our full-year range of $450 to $550 million of new product launches," said Viatris CFO Doretta Mistras.
維亞特里斯首席財務官多雷塔·米斯特拉斯表示：“由於我們的基本面和業務勢頭，我們認爲我們完全有能力實現2024年的財務指導，以及全年4.5億美元至5.5億美元的新產品發佈區間。”
Sales of the cholesterol medication Lipitor declined from $417.9 million to $388.9 million, and sales of Norvasc for high blood pressure reached $176.3 million, down from $202.7 million.
膽固醇藥物立普妥的銷售額從4.179億美元下降至3.889億美元，Norvasc用於高血壓的銷售額從2.027億美元降至1.763億美元。
Guidance: Viatris expects 2024 adjusted EPS of $2.66-$2.81, compared to prior guidance of $2.70-$2.85 and the consensus of $2.74.
指導方針：維亞特里斯預計，2024年調整後的每股收益爲2.66-2.81美元，而之前的預期爲2.70美元至2.85美元，共識爲2.74美元。
The company forecasts revenues of $14.98 billion—$15.48 billion, versus a consensus of $15.19 billion and prior guidance of $15.25 billion—$15.75 billion.
該公司預計收入爲149.8億美元至154.8億美元，而市場普遍預期爲151.9億美元，之前的預期爲152.5億美元至157.5億美元。
The company expects total revenues to be slightly higher in the second half vs. the first half of 2024, driven by normal product seasonality.
該公司預計，受正常產品季節性的推動，下半年的總收入將比2024年上半年略有增加。
Adjusted EBITDA is expected to be $4.71 billion-$5.01 billion.
調整後的息稅折舊攤銷前利潤預計爲47.1億美元至50.1億美元。
Viatris expects adjusted EBITDA and EPS to be slightly higher in the second half vs. the first half 2024.
維亞特里斯預計，下半年調整後的息稅折舊攤銷前利潤和每股收益將略高於2024年上半年。
Adjusted gross margin is expected to moderate in the second half due to segment and product mix.
由於細分市場和產品組合，調整後的毛利率預計將在下半年放緩。
Price Action: VTRS shares were down 4.61% at $11.27 at last check Thursday.
價格走勢：週四最後一次檢查時，VTRS股價下跌4.61％，至11.27美元。